title: Kidney cancer, version 2.2014.
abstract: These NCCN Guidelines Insights highlight treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma included in the 2014 version of the NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer.
authors.affiliation: From 1Memorial Sloan-Kettering Cancer Center; 2The University of Texas MD Anderson Cancer Center; 3Huntsman Cancer Institute at the University of Utah; 4Dana-Farber/Brigham and Women's Cancer Center; 5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 6University of Alabama at Birmingham Comprehensive Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8UC San Diego Moores Cancer Center; 9Moffitt Cancer Center; 10Stanford Cancer Institute; 11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 12Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 13University of Colorado Cancer Center; 14City of Hope Comprehensive Cancer Center; 15Roswell Park Cancer Institute; 16Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 17Massachusetts General Hospital Cancer Center 18The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 19Fox Chase Cancer Center; 20Duke Cancer Institute; 21University of Michigan Comprehensive Cancer Center; 22UCSF Helen Diller Family Comprehensive Cancer Center; 23St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 24Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; and 25National Comprehensive Cancer Network.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
authors.forename: Neeraj
authors.initials: N
authors.lastname: Agarwal
authors.forename: Clair
authors.initials: C
authors.lastname: Beard
authors.forename: Sam
authors.initials: S
authors.lastname: Bhayani
authors.forename: Graeme B
authors.initials: GB
authors.lastname: Bolger
authors.forename: Sam S
authors.initials: SS
authors.lastname: Chang
authors.forename: Toni K
authors.initials: TK
authors.lastname: Choueiri
authors.forename: Ithaar H
authors.initials: IH
authors.lastname: Derweesh
authors.forename: Shilpa
authors.initials: S
authors.lastname: Gupta
authors.forename: Steven L
authors.initials: SL
authors.lastname: Hancock
authors.forename: Jenny J
authors.initials: JJ
authors.lastname: Kim
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Kuzel
authors.forename: Elaine T
authors.initials: ET
authors.lastname: Lam
authors.forename: Clayton
authors.initials: C
authors.lastname: Lau
authors.forename: Ellis G
authors.initials: EG
authors.lastname: Levine
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Lin
authors.forename: Kim A
authors.initials: KA
authors.lastname: Margolin
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson
authors.forename: Thomas
authors.initials: T
authors.lastname: Olencki
authors.forename: Roberto
authors.initials: R
authors.lastname: Pili
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
authors.forename: Edward N
authors.initials: EN
authors.lastname: Rampersaud
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Redman
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Ryan
authors.forename: Joel
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: Kanishka
authors.initials: K
authors.lastname: Sircar
authors.forename: Brad
authors.initials: B
authors.lastname: Somer
authors.forename: Jue
authors.initials: J
authors.lastname: Wang
authors.forename: Richard B
authors.initials: RB
authors.lastname: Wilder
authors.forename: Mary A
authors.initials: MA
authors.lastname: Dwyer
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors